Also trades as: TVGNW (NASDAQ) · $vol 0M
TVGN NASDAQ
Tevogen Bio Holdings Inc.
1W: +24.5%
1M: +44.1%
3M: -16.4%
YTD: +3124.3%
1Y: +911.2%
3Y: +4.7%
$9.61
-1.90 (-16.51%)
Weekly Expected Move ±25.1%
$4
$6
$8
$11
$13
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (25)
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
Tevogen Bio Holdings reports Q1 results; operating loss falls 48%
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
Tevogen Bio Explores Buyout To Boost Generics Platform
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical
Tevogen approves 1-for-50 reverse share split
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue
Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
Tevogen CEO Donates Personal Shares to Support Local Fire Department
Tevogen Bio (NASDAQ:TVGN) Trading Down 1.8% – Time to Sell?
Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook